$5.10 $0.05 (1.0%)

04:00 PM EDT on 10/11/19

Kamada (NASDAQ:KMDA)

CAPS Rating: No stars

Current Price $5.10 Mkt Cap $725.6M
Open $5.04 P/E Ratio 0.00
Prev. Close $5.05 Div. (Yield) $0.00 (0.0%)
Daily Range $5.04 - $5.10 Volume 1,771
52-Wk Range $4.97 - $6.70 Avg. Daily Vol. 1

Caps

How do you think NASDAQ:KMDA will perform against the market?

Add Stock to CAPS Watchlist

All Players

8 Outperform
1 Underperform
 

All-Star Players

3 Outperform
0 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:KMDA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.82)
Submitted July 05, 2014

Kamada is kind of a weird company. Aside from being an Israeli biotech, which I've found to be a highly weird niche of the biopharma sector, the company offers a strange mix of marketed products and therapeutics in clinical development.The company's… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:KMDA VS S&P 500 (SPY)

Fools bearish on NASDAQ:KMDA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about KMDA.

Recs

5
Member Avatar zzlangerhans (99.82) Submitted: 7/4/2014 9:58:03 PM : Outperform Start Price: $7.21 NASDAQ:KMDA Score: -78.83

Kamada is kind of a weird company. Aside from being an Israeli biotech, which I've found to be a highly weird niche of the biopharma sector, the company offers a strange mix of marketed products and therapeutics in clinical development.The company's lead product, Glassia, is a plasma-purified alpha-1 antitrypsin (AAT) administered intravenously for congenital AAT deficiency. It may seem odd that Kamada's market capitalization is only 250M given the high valuation assigned to other companies marketing enzyme replacement therapies and other protein therapeutics for rare diseases, but Glassia is in fact the fourth plasma derived AAT to become available, and intravenous AAT doesn't seem to be the cornerstone of therapy for AAT deficiency.

Kamada IPO'd in early 2013 and seems to have dedicated the bulk of the cash they raised to their developmental pipeline, which mainly consists of a novel inhalational AAT as well as broadening the indications for Glassia. That effort took a serious body blow with the failure of a European phase II/III trial of inhaled AAT to meet the primary endpoint in May, resulting in a substantial haircut in share price from a high of 18 to a recent low of 7. Nevertheless, Kamada seems to be pressing ahead with new trials of inhaled AAT in emphysema from AAT deficiency. Trials of Glassia in GVHD and type I diabetes are also in progress.

Kamada's long-term prospects seem dubious but at some point the share price will level off and begin to rise again as traders become optimistic about trials in progress. I'm not sure that time has come, but I'll flag Kamada with a green thumb here to remind me to keep a close eye on the price movement as the pipeline progresses.

Leaderboard

Find the members with the highest scoring picks in KMDA.

Score Leader

XMFCouchSurfer

XMFCouchSurfer (61.76) Score: +79.23

The Score Leader is the player with the highest score across all their picks in KMDA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
XMFCouchSurfer 61.76 7/29/2014 Underperform 5Y $7.19 -29.07% +50.16% +79.23 0 Comment
billator 99.22 8/6/2019 Outperform 5Y $5.53 -7.78% +2.90% -10.68 0 Comment
Under5 < 20 9/27/2017 Outperform 5Y $4.75 +7.37% +18.80% -11.43 0 Comment
cvdynasty0 99.95 9/4/2014 Outperform 5Y $5.82 -12.37% +47.23% -59.60 0 Comment
zzlangerhans 99.82 7/3/2014 Outperform 1Y $7.21 -29.26% +49.56% -78.83 1 Comment
joe508mama 30.98 5/19/2014 Outperform 5Y $8.50 -40.00% +57.28% -97.28 0 Comment
gust89 < 20 5/19/2014 Outperform 1Y $8.61 -40.77% +57.82% -98.59 0 Comment
tat2matt < 20 1/7/2014 Outperform 5Y $15.40 -66.88% +61.79% -128.67 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackOppenheimer < 20 6/25/2013 Outperform NS $10.83 -52.91% +86.91% -139.82 0 Comment